UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


SCHEDULE 13G
(Amendment No. 2)


UNDER THE SECURITIES EXCHANGE ACT OF 19341


Anthera Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, $0.001 par value
(Title of Class of Securities)

03674U102
(CUSIP Number)

December 31, 2015
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
☒ Rule 13d-1(c)
Rule 13d-1(d)


_______________

1   The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




CUSIP No. 03674U102
13G
Page 2 of 11 Pages


 
1.
 
 
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Investments IV, L.P.                                                                                          20-5935001
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**
 
(a)
(b) ☒
 
 
3.
 
 
SEC USE ONLY
 
 
 
4.
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
 
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
 
 
5.
 
 
SOLE VOTING POWER
-0-
 
 
6.
 
 
SHARED VOTING POWER
1,900,000
 
 
7.
 
 
SOLE DISPOSITIVE POWER
-0-
 
 
8.
 
 
SHARED DISPOSITIVE POWER
1,900,000
 
 
9.
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,900,000
 
 
10.
 
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**
 
 
 
11.
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%
 
 
12.
 
 
TYPE OF REPORTING PERSON**
PN
 
 
 
** SEE INSTRUCTIONS BEFORE FILLING OUT
 





CUSIP No. 03674U102
13G
Page 3 of 11 Pages


 
1.
 
 
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Associates IV LLC                                                                                          20-5934968
 
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**
 
 
(a)
(b) ☒
 
 
 
3.
 
 
SEC USE ONLY
 
 
 
4.
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
 
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
 
 
5.
 
 
SOLE VOTING POWER
-0-
 
 
6.
 
 
SHARED VOTING POWER
1,900,000
 
 
7.
 
 
SOLE DISPOSITIVE POWER
-0-
 
 
8.
 
 
SHARED DISPOSITIVE POWER
1,900,000
 
 
9.
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,900,000
 
 
10.
 
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**
 
 
 
11.
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%
 
 
12.
 
 
TYPE OF REPORTING PERSON**
OO
 
 
 
** SEE INSTRUCTIONS BEFORE FILLING OUT
 




CUSIP No. 03674U102
13G
Page 4 of 11 Pages


 
1.
 
 
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Jay Moorin
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**
 
(a)
(b) ☒
 
 
3.
 
 
SEC USE ONLY
 
 
 
4.
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
 
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
 
 
5.
 
 
SOLE VOTING POWER
-0-
 
6.
 
 
SHARED VOTING POWER
1,900,000
 
 
7.
 
 
SOLE DISPOSITIVE POWER
-0-
 
 
8.
 
 
SHARED DISPOSITIVE POWER
1,900,000
 
 
9.
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,900,000
 
 
10.
 
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**
 
 
 
11.
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%
 
 
12.
 
 
TYPE OF REPORTING PERSON**
IN
 
 
 
** SEE INSTRUCTIONS BEFORE FILLING OUT





CUSIP No. 03674U102
13G
Page 5 of 11 Pages


 
1.
 
 
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alain Schreiber
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**
 
(a)
(b) ☒
 
 
3.
 
 
SEC USE ONLY
 
 
 
4.
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
 
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
 
 
5.
 
 
SOLE VOTING POWER
-0-
 
6.
 
 
SHARED VOTING POWER
1,900,000
 
 
7.
 
 
SOLE DISPOSITIVE POWER
-0-
 
 
8.
 
 
SHARED DISPOSITIVE POWER
1,900,000
 
 
9.
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,900,000
 
 
10.
 
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**
 
 
 
11.
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%
 
 
12.
 
 
TYPE OF REPORTING PERSON**
IN
 
 
 
** SEE INSTRUCTIONS BEFORE FILLING OUT





CUSIP No. 03674U102
13G
Page 6 of 11 Pages


Item 1(a).
Name of Issuer.

Anthera Pharmaceuticals, Inc. (the "Company").
Item 1(b).
Address of Issuer's Principal Executive Offices.

The Company's principal executive offices are located at 25801 Industrial boulevard, Suite B, Hayward, California 94545.
Items 2(a).
Name of Person Filing.

This statement is filed on behalf of the following persons with respect to shares of common stock of the Company and shares of common stock of the Company issuable upon the exercise of warrants (collectively, the "Shares"):
(i)            ProQuest Investments IV, L.P., a Delaware limited partnership ("Investments IV"), with respect to Shares beneficially owned by it;
(ii)            ProQuest Associates IV LLC, a Delaware limited liability company ("Associates IV"), as General Partner of Investments IV with respect to Shares beneficially owned by Investments IV;
(iii)            Jay Moorin, an individual and a member of Associates IV ("Moorin"), with respect to Shares beneficially owned by Associates IV; and
(iv)            Alain Schreiber, an individual and a member of Associates IV ("Schreiber"), with respect to Shares beneficially owned by Associates IV.
The foregoing persons are hereinafter are referred to collectively as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

Item 2(b).
Address of Principal Business Office or, if None, Residence.

The address of the principal business office of each of the Reporting Persons is 2430 Vanderbilt Beach Road, 108-190, Naples, FL  34109.
Item 2(c).
Citizenship.

Mr. Moorin is a United States citizen.  Mr. Schreiber is a United States resident alien.  Investors IV is a Delaware limited partnership organized under the laws of the State of Delaware.  Associates IV is a Delaware limited liability company organized under the laws of the State of Delaware.
Item 2(d).
Title of Class of Securities.

Common stock, par value $0.001 per share.




CUSIP No. 03674U102
13G
Page 7 of 11 Pages


Item 2(e).
CUSIP Number.

03674U102
Item 3.
 

If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:
 
(a)
Broker or dealer registered under Section 15 of the Act,
 
(b)
Bank as defined in Section 3(a)(6) of the Act,
 
(c)
Insurance Company as defined in Section 3(a)(19) of the Act,
 
(d)
Investment Company registered under Section 8 of the Investment Company Act of 1940,
 
(e)
Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
 
(f)
Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
 
(g)
Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
 
(h)
Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
 
(i)
Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
 
(j)
A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
 
(k)
Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________


Item 4.
Ownership.

The percentages used herein are calculated based upon 39,875,405 shares issued and outstanding as of November 1, 2015, as reported in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015, filed with the SEC on November 9, 2015.  All share amounts in this Schedule 13G take into account the 1-for-8 stock split effected by the Company in July 2013.  As of the close of business on December 31, 2015, the Reporting Persons beneficially owned shares of the Company's common stock in the amounts and percentages listed below:

 
A.
ProQuest Investments IV, L.P.
 
 
(a)
Amount beneficially owned:  1,900,000
 
 
 




CUSIP No. 03674U102
13G
Page 8 of 11 Pages


 
 
 
(b)
Percent of class:  4.8%
 
(c)
(i)
Sole power to vote or direct the vote:  -0-
   
(ii)
Shared power to vote or direct the vote:  1,900,000
   
(iii)
Sole power to dispose or direct the disposition:  -0-
   
(iv)
Shared power to dispose or direct the disposition:  1,900,000
 
B.
ProQuest Associates IV LLC
 
(a)
Amount beneficially owned:  1,900,000 
 
(b)
Percent of class:  4.8%
 
(c)
(i)
Sole power to vote or direct the vote:  -0-
   
(ii)
Shared power to vote or direct the vote: 1,900,000
   
(iii)
Sole power to dispose or direct the disposition:  -0-
   
(iv)
Shared power to dispose or direct the disposition:  1,900,000
 
C.
Jay Moorin 
 
(a)
Amount beneficially owned:   1,900,000 
 
(b)
Percent of class:  4.8%
 
 
(c)
(i)
Sole power to vote or direct the vote:  -0-
   
(ii)
Shared power to vote or direct the vote:  1,900,000
   
(iii)
Sole power to dispose or direct the disposition:  -0-
   
(iv)
Shared power to dispose or direct the disposition:  1,900,000
 
D.
Alain Schreiber 
 
(a)
Amount beneficially owned:  1,900,000 
 
(b)
Percent of class:  4.8% 
 
(c)
(i)
Sole power to vote or direct the vote:  -0-
   
(ii)
Shared power to vote or direct the vote:  1,900,000
   
(iii)
Sole power to dispose or direct the disposition:  -0-
   
(iv)
Shared power to dispose or direct the disposition:  1,900,000

Item 5.
Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.

To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares




CUSIP No. 03674U102
13G
Page 9 of 11 Pages


which represents more than five percent of the number of outstanding shares of the Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable.
Item 8.
Identification and Classification of Members of the Group.

Not Applicable.
Item 9.
Notice of Dissolution of Group.

Not Applicable.
Item 10.
Certifications.

Each of the Reporting Persons hereby makes the following certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



CUSIP No. 03674U102
13G
Page 10 of 11 Pages

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED:  February 12, 2016
   
    /s/ Pasquale DeAngelis
   
Pasquale DeAngelis, as a member of ProQuest Associates IV LLC and on behalf of ProQuest Investments IV, L.P.
     
     
   
*
   
Jay Moorin, individually
     
     
   
*
   
Alain Schreiber, individually


*By:
/s/ Pasquale DeAngelis   
 
Pasquale DeAngelis, Attorney-in-Fact
 






CUSIP No. 03674U102
13G
Page 11 of 11 Pages

Index Exhibit
SCHEDULE 13G

 
Exhibit Number
 
Exhibit Description
24.1
Power of Attorney*
 
99.1
Joint Filing Agreement*
 
* Previously filed.


Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.